Matthew S. Berlinger, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
Matt Sorrells, Cytovale, Inc, San Francisco, CA
Christopher B. Thomas, Franciscan Missionaries of Our Lady Health System, Baton Rouge, LA
Tonya Jagneaux, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
James E. Walker, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
Jennifer Daigle, LSU Health Sciences Center - New OrleansFollow
Heather Quiriarte, Louisiana State University, Baton Rouge, LA
Youyoung Kim, Louisiana State University, Baton Rouge, LA
Guillaume Spielmann, Louisiana State University, Baton Rouge, LA
Debbie Robertson, Johns Hopkins University, Baltimore, MD
Susan Park Ochsner, Johns Hopkins University, Baltimore, MD
Gideon Avornu, Johns Hopkins University, Baltimore, MD
Katherine Fenstermacher, Johns Hopkins University, Baltimore, MD
Elijah James Kurien, Johns Hopkins University, Baltimore, MD
Camille King, Johns Hopkins University, Baltimore, MD
Adenine Cembellin-Kao, Johns Hopkins University, Baltimore, MD
Chase Yonamine, Johns Hopkins University, Baltimore, MD
Querino Maia, Johns Hopkins University, Baltimore, MD
Maciej Obrebski, Johns Hopkins University, Baltimore, MD
David N. Hager, Johns Hopkins University, Baltimore, MD
Roya Sheybani, Cytovale, Inc, San Francisco, CA
Henry T.K. Tse, Cytovale, Inc, San Francisco, CA
Ajay M. Shah, Cytovale, Inc, San Francisco, CA
Robert Scoggins, Kootenai Health, Coeur d'Alene, ID
Hollis R. O’Neal, LSU Health Sciences Center - New OrleansFollow
Richard Rothman, Johns Hopkins University, Baltimore, MD

Document Type

Article

Publication Date

8-20-2025

Publication Title

Scientific Reports

Abstract

Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, ISI values declined, reflecting the patient’s response to treatment, with Band 3 patients showing a 20% decline within the first two days of admission. ISI trends preceded Sequential Organ Failure Assessment (SOFA) score changes by two days. ISI also provided more stable and timely disease state assessments compared to traditional biomarkers (PCT, CRP, IL-6, and neutrophil elastase). Larger studies are needed to validate these findings and assess ISI’s clinical utility as a prognosticator of sepsis progression and treatment response.

PubMed ID

40836052

Volume

15

Issue

1

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS